next chapter of the J. Safra Sarasin Group. Your role As a CRM Assistant in Private Banking you will support the Client.... Please note that if you submit your application, Bank J. Safra Sarasin Ltd will process your personal data for the purpose of the...
next chapter of the J. Safra Sarasin Group. Your role Do you want to be part of an international team with focus on regulatory... transformation? Take your chance and apply as a resource for the Business & Regulatory Development department of Bank J. Safra...
geprägt wird. Schliessen Sie sich unserem internationalen Team an und werden Sie Teil des nächsten Kapitels der J. Safra... Sarasin Gruppe. Ihre Rolle Als Fachspezialist/in Zahlungsverkehr bei der Bank J. Safra Sarasin unterstützen Sie unser Team...
next chapter of the J. Safra Sarasin Group. Your role As IAM Role Engineer at Bank J. Safra Sarasin you are part of the... that only direct applications will be considered. Please note that if you submit your application, Bank J. Safra Sarasin Ltd...
Chile, home to the world’s biggest lithium reserves, is confident that investors will compete for licenses to drill new deposits even amid a worsening global glut that’s squeezing the battery-metal industry. Continue Reading »
Gold Prices Today: Gold of 99.9 and 99.5 per cent purity grew ₹2,320 each in the last seven trading sessions. However, silver prices declined ₹500 to ₹93,500 per kg from the previous close Continue Reading »
At 11:57 a.m. ET, the Dow Jones Industrial Average rose 0.58 per cent, the S&P 500 gained 0.14 per cent, the Nasdaq Composite lost 0.19 per cent Continue Reading »
Expert view: Mohit Khanna anticipates the Union Budget 2025 will prioritize youth, women, the poor, and farmers, with increased spending on rural housing, irrigation, and employment-linked incentives. Continue Reading »
HPCL Q3 Results: The state-owned OMC's revenue from operations in the third quarter of current fiscal rose to ₹1.10 lakh crore led by better marketing margins. Continue Reading »
Dr Reddy's Laboratories reported a 2% YoY increase in PAT to ₹1,413.3 crore for Q3 2024, driven by a 16% rise in revenue to ₹8,358.6 crore. The company invested ₹6.7 billion in R&D, focusing on complex generics and biosimilars. Continue Reading »